{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:25:42Z","timestamp":1787923542728,"version":"build-2784847793"},"reference-count":16,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Pers. Med.","JPM"],"abstract":"<jats:p>Background: Secondary cytoreductive surgery (SCS) followed by postoperative chemotherapy is a recognized option for select patients with platinum-sensitive first recurrent epithelial ovarian cancer (EOC), supported by the DESKTOP-III and SOC-1 trials. Neither trial reported chemotherapy rates stratified by lesion number or resection status. As a result, the added value of postoperative chemotherapy after complete resection of a unifocal recurrence remains unclear. This study aimed to evaluate current clinical practice and factors influencing this decision. Methods: A cross-sectional survey was conducted among gynecological and medical oncologists from international expert oncological centers, assessing definitions of unifocal recurrence, current postoperative chemotherapy practice after complete SCS, perceived clinical value and strength of the supporting evidence, and factors influencing decision-making. Results: Twenty of 48 invited experts responded (41.7%). Respondents applied different definitions of unifocal recurrence, leading to variable estimates of the annual number of patients undergoing SCS. Respondents perceived postoperative chemotherapy to have meaningful clinical value, despite rating the supporting evidence as weak. A proportion did not routinely administer postoperative chemotherapy after complete SCS, managing patients with observation alone. Decisions to omit chemotherapy were influenced by institutional, clinical, and patient-related factors. Overall, 82% of respondents considered a randomized trial comparing chemotherapy with observation clinically valuable. Conclusions: Clinical practice regarding postoperative chemotherapy after complete SCS for a first unifocal recurrence of EOC varies among international expert oncological centers. The absence of a uniform definition of unifocal recurrence and lack of direct evidence regarding postoperative chemotherapy omission highlight the need for standardized definitions and prospective randomized evaluation of chemotherapy versus observation.<\/jats:p>","DOI":"10.3390\/jpm16090449","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:27:46Z","timestamp":1787920066000},"page":"449","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Decision-Making Regarding the Added Value of Postoperative Chemotherapy After Complete Secondary Cytoreductive Surgery in Unifocal First Recurrent Epithelial Ovarian Cancer\u2014An International Expert Survey"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3260-2148","authenticated-orcid":false,"given":"Ren\u00e9e E. W. M.","family":"van de Vorst","sequence":"first","affiliation":[{"name":"Department of Gynecological Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie S. M.","family":"Pelk","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7390-0761","authenticated-orcid":false,"given":"Eelke H.","family":"Gort","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-3075","authenticated-orcid":false,"given":"Petronella O.","family":"Witteveen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1829-7773","authenticated-orcid":false,"given":"Ronald P.","family":"Zweemer","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-2258","authenticated-orcid":false,"given":"Cornelis G.","family":"Gerestein","sequence":"additional","affiliation":[{"name":"Department of Gynecological Oncology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: The Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Climent, M.T., Serra, A., Llueca, M., and Llueca, A. (2023). Surgery in Recurrent Ovarian Cancer: A Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15133470"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1245\/s10434-020-09226-7","article-title":"The Role of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis","volume":"28","author":"Marchetti","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","article-title":"Surgery versus No Surgery in Platinum-Sensitive Relapsed Ovarian Cancer: Final Overall Survival Analysis of the SOC-1 Randomized Phase 3 Trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary Cytoreduction Followed by Chemotherapy versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer (SOC-1): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejso.2004.08.016","article-title":"Surgical Cytoreduction in Recurrent Ovarian Carcinoma in Patients with Complete Response to Paclitaxel-Platinum","volume":"31","author":"Gronlund","year":"2005","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/cncr.22447","article-title":"Secondary Cytoreductive Surgery for Localized, Recurrent Epithelial Ovarian Cancer: Analysis of Prognostic Factors and Survival Outcome","volume":"109","author":"Salani","year":"2007","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.gore.2025.101809","article-title":"The Added Value of Chemotherapy after Secondary Cytoreductive Surgery in Unifocal versus Multifocal First Recurrent Epithelial Ovarian Cancer: A Systematic Review","volume":"60","author":"Huiskamp","year":"2025","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.ygyno.2021.10.008","article-title":"Secondary Cytoreductive Surgery for Recurrent Ovarian Cancer: An SGO Clinical Practice Statement","volume":"163","author":"Harrison","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology and Early, Advanced and Recurrent Disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_14","unstructured":"Castor EDC (2026, February 01). Castor Electronic Data Capture. Available online: https:\/\/castoredc.com."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13012-022-01245-0","article-title":"The Updated Consolidated Framework for Implementation Research Based on User Feedback","volume":"17","author":"Damschroder","year":"2022","journal-title":"Implement. Sci."},{"key":"ref_16","unstructured":"Posit Team (2025). RStudio: Integrated Development Environment for R, Posit Software PBC. Available online: http:\/\/www.posit.co\/."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/449\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:41:43Z","timestamp":1787920903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/16\/9\/449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jpm16090449"],"URL":"https:\/\/doi.org\/10.3390\/jpm16090449","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}